Clinical Evidence Review: Melanotan II and Cartalax in Skin Health and Aging Models

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

1. Clinical Question

How do non-selective melanocortin agonists and small peptide bioregulators influence skin pigmentation and cellular markers associated with aging, and what is the current quality of human clinical evidence supporting their use?

2. Evidence Snapshot

• Melanotan II
  • Evidence Grade: C
  • Study Types: Clinical observation and laboratory research.
  • Outcomes: Confirmed stimulation of melanogenesis (skin darkening).
  • Regulatory Status: Not approved; FDA and TGA safety communications issued.
• Cartalax (AED Peptide)
  • Evidence Grade: C (Low-confidence; borderline C/D if patent-only data is excluded).
  • Study Types: Single small human study (unregistered) and preclinical models (skin/kidney aging).
  • Sample Size: 29 subjects in a knee osteoarthritis study; preclinical data on cartilage explants.
  • Outcomes: Reported pain/mobility improvement in 54.5–62.7% of OA subjects; no radiographic improvement.

3. What the Research Shows

Evidence regarding peptides for skin-related applications is categorized by distinct functional goals: pigmentation and cellular aging protection.

Melanotan II Research confirms that Melanotan II stimulates melanogenesis, leading to skin darkening. This compound was originally developed at the University of Arizona. While the effect on tanning is confirmed, the evidence points toward significant concerns regarding non-selective receptor activation and potential melanoma promotion.

Cartalax (AED Peptide) Human data for Cartalax is currently limited to a single unregistered human patent example involving 29 patients with knee osteoarthritis. In this study, subjects received intramuscular dosing (1 µg–5 mg daily) for 20 days. While 54.5–62.7% of subjects reported improvements in pain and mobility, no changes were observed in radiographic imaging. Preclinical investigations have explored the peptide's role in aging models, including studies on skin aging and old-rat nephroprotection. Laboratory findings indicate it may influence chondrocyte proliferation by 1.4–2.1 times at concentrations of 200 ng/mL.

4. Mechanism

Melanotan II Melanotan II acts as a non-selective melanocortin receptor agonist, binding to receptors MC1R through MC5R. While its action at MC1R stimulates pigmentation, its non-selective nature leads to the activation of other pathways. This includes MC3R and MC4R, which influence appetite and sexual function, as well as MC5R, which is located in the sebaceous glands.

Cartalax (Ala-Glu-Asp) Cartalax is a tripeptide (MW 333.29 g/mol) proposed to normalize metabolism via the modulation of gene expression. In preclinical models, it has been shown to influence markers associated with aging and cellular health, including SIRT1, SIRT6, Ki-67, and p53. Furthermore, it is suggested to modulate chondrocyte gene expression, specifically targeting SOX9, aggrecan, type II collagen, and COMP.

5. Limitations of the Evidence

Melanotan II The primary limitation of Melanotan II is its non-selective receptor activation, which results in multiple off-target effects. Significant safety concerns exist regarding melanoma promotion. Both the FDA and the TGA have issued formal safety communications, and the compound is not currently approved for clinical use.

Cartalax The human evidence for Cartalax is considered low-confidence. Data rests entirely on a single, difficult-to-audit patent narrative (RU2299741C1 / WO2007139433A1) which contains internal inconsistencies regarding dose rationale. There are no registered clinical trials, no Phase III data, and no Adverse Event (AE) tables provided. It lacks approval from the FDA or EMA, though it is sold in Russia as a dietary supplement. Furthermore, the human studies provided primarily focus on osteoarthritis rather than direct skin clinical trials, despite the existence of preclinical skin aging models.

6. Clinical Takeaway

While Melanotan II is effective at inducing skin darkening, its use is complicated by non-selective receptor binding and critical safety warnings from regulatory bodies. Cartalax remains in the early stages of evidence, with its clinical claims based on limited patent-embedded data and preclinical aging models. Neither compound is FDA-approved, and the quality of evidence supporting their widespread clinical application for skin health remains Grade C or lower.

7. Sources

• TruthTides Database: Melanotan II (Grade C) - Non-selective melanocortin receptor agonist.
• TruthTides Database: Cartalax (Grade C) - Patent family RU2299741C1 / WO2007139433A1 / EA010574B1.